Dickson-Gomez Julia, Christenson Erika, Weeks Margaret, Galletly Carol, Wogen Jennifer, Spector Antoinette, McDonald Madelyn, Ohlrich Jessica
Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, USA.
Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, WI, USA.
Subst Abuse. 2021 Mar 25;15:1178221821992349. doi: 10.1177/1178221821992349. eCollection 2021.
Prescription Drug Monitoring Programs (PDMPs) were designed to curb opioid misuse and diversion by tracking scheduled medications prescribed by medical providers and dispensed by pharmacies. The effects of PDMPs on opioid prescription, misuse and overdose rates have been mixed due in part to variability in states' PDMPs and difficulties measuring this complexity, and a lack of attention to implementation and enforcement of PDMP components. The current study uses qualitative interviews with key informants from 3 states with different PDMPs, Connecticut, Kentucky and Wisconsin to explore differences in the characteristics of the PDMPs in each state; how they are implemented, monitored and enforced; and unintended negative consequences of these programs.
We conducted in-depth interviews with key informants from each state representing the following sectors: PDMP and pain clinic regulation agencies, Medicaid programs, state licensing boards, pharmacies, emergency medicine departments, pain management clinics, first responders, drug courts, drug treatment programs, medication assisted treatment (MAT) providers, and harm reduction organizations. Interview guides explored participants' experiences with and opinions of PDMPs according to their roles. Data analysis was conducted using a collaborative, constant comparison method.
While all 3 states had mandated registration and reporting requirements, the states differed in the implementation and enforcement of these and the extent to which provider prescribing was monitored. These, in turn, influenced how medical providers perceived the PDMP and changed how providers prescribed opioids. Unintended consequences of state PDMPs included under-prescribing for pain and "dumping" patients who were long term users of opioids or who had developed opioid use disorders and may explain the increase in illicit heroin or opioid use.
State PDMPs with similar mandates may differ greatly in implementation and enforcement. These differences are important to consider when determining the effects of PDMPs on opioid misuse and overdose.
处方药监测计划(PDMPs)旨在通过追踪医疗服务提供者开具并由药房配药的处方药,来遏制阿片类药物的滥用和转移。PDMPs对阿片类药物处方、滥用及过量使用率的影响参差不齐,部分原因在于各州PDMPs存在差异,且难以衡量这种复杂性,同时也缺乏对PDMP各组成部分实施与执行情况的关注。本研究通过对来自康涅狄格州、肯塔基州和威斯康星州这三个具有不同PDMPs的州的关键信息提供者进行定性访谈,来探讨各州PDMPs在特征方面的差异;它们是如何实施、监测和执行的;以及这些计划意外产生的负面后果。
我们对来自各州代表以下部门的关键信息提供者进行了深入访谈:PDMP和疼痛诊所监管机构、医疗补助计划、州许可委员会、药房、急诊科、疼痛管理诊所、急救人员、毒品法庭、戒毒治疗项目、药物辅助治疗(MAT)提供者以及减少伤害组织。访谈指南根据参与者的角色,探讨了他们对PDMPs的经历和看法。采用协作式、持续比较法进行数据分析。
虽然所有三个州都规定了注册和报告要求,但各州在这些要求的实施和执行以及对医疗服务提供者处方监测的程度方面存在差异。这些差异进而影响了医疗服务提供者对PDMP的看法,并改变了他们开具阿片类药物的方式。各州PDMPs意外产生的后果包括对疼痛治疗的处方不足,以及“抛弃”长期使用阿片类药物或已出现阿片类药物使用障碍的患者,这可能解释了非法海洛因或阿片类药物使用的增加。
具有相似授权的各州PDMPs在实施和执行方面可能存在很大差异。在确定PDMPs对阿片类药物滥用和过量使用的影响时,这些差异很重要,需要加以考虑。